Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 27

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 27
---
          
 fee, which will only become payable if and when we receive $25.0 million aggregate gross proceeds from sales of common stock to Lincoln Park under the Purchase Agreement, in shares of our common stock. The [ ] shares listed as                        
 beneficially owned represent shares purchased under the Purchase Agreement. Furthermore, under the terms of the Purchase Agreement, issuances and sales of shares of our common stock to Lincoln Park under the Purchase Agreement are subject to certain 
 limitations on the amounts we may sell to Lincoln Park at any time, including the Beneficial Ownership Cap.                                                                                                                                               |

| (3) | Although the Purchase Agreement provides that we may sell up to $[ ] million of our common stock to                                                                                                                                                      
 Lincoln Park, we are only registering 15,000,000 shares of our common stock for resale under this prospectus Depending on the price per share at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell  
 to Lincoln Park under the Purchase Agreement more shares of our common stock than are offered under this prospectus in order to receive aggregate gross proceeds equal to the full $[ ] million available to us under the Purchase Agreement. If we      
 choose to do so, we must again register for resale under the Securities Act such additional shares. The number of shares ultimately offered for resale by Lincoln Park is dependent upon the number of shares we sell to Lincoln Park under the Purchase 
 Agreement.                                                                                                                                                                                                                                               |

16

Confidential Treatment Requested by Plus Therapeutics, Inc.

Pursuant to 17 C.F.R. Section 200.83

MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS

Market Information

Our common
stock is traded on the Nasdaq Capital Market under the symbol “PSTV”.

Holders

As of [ ], 2025, there were approximately [ ] registered holders of our common stock. This number does not include stockholders for
whom shares were held in “nominee” or “street name.”

Dividend Policy

We have never declared or paid any cash dividends on our common stock and we do not intend to pay cash dividends in the foreseeable future. We
currently expect to retain any future earnings to fund the operation and expansion of our business.

17

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 DESCRIPTION OF CAPITAL STOCK This section describes the general terms and provisions of the shares of our common stock, par value